CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Explore linked clinical trials.19 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia | Diagnosed With HoFH | Recruiting | Phase 2 | 2026-07-31 | NCT07591298 | |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Not yet recruiting | Phase 3 | 2026-07-29 | NCT07735117 | |
| A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 2 | 2026-07-22 | NCT07695597 | |
| A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | Heterozygous Familial Hypercholesterolemia (HeFH) | Recruiting | Phase 3 | 2026-07-08 | NCT07465263 | |
| A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a) | Adult Participants With Elevated Lipoprotein(a) | Not yet recruiting | Phase 2 | 2026-06-10 | NCT07640217 | |
| A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension | resistant hypertension | Not yet recruiting | Phase 3 | 2026-06-09 | NCT07635914 | |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061 | Healthy Subjects | Recruiting | Phase 1 | 2026-06-08 | NCT07241910 | |
| Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Not yet recruiting | Not applicable | 2026-04-23 | NCT07547384 | |
| A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 3 | 2026-04-07 | NCT07421297 | |
| A Bioequivalence Study of PP3M in Patients With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Not applicable | 2026-03-25 | NCT07493551 | |
| Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 3 | 2026-03-20 | NCT07486479 | |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Not yet recruiting | Phase 3 | 2026-02-19 | NCT07421284 | |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 / Phase 2 | 2026-01-08 | NCT06265727 | |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection | Healthy Subjects (HS) | Recruiting | Phase 1 | 2025-12-01 | NCT07241923 | |
| Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, myeloid neoplasm, neoplasm | Recruiting | Phase 2 | 2025-09-16 | NCT06621212 | |
| Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients | Bioequivalence | Recruiting | Phase 1 | 2025-07-31 | NCT07096869 | |
| Study of SYH2062 Injection in Healthy Chinese Volunteers | Healthy Chinese Volunteers | Recruiting | Phase 1 | 2025-04-30 | NCT06842537 | |
| Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2024-10-01 | NCT06621199 | |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 3 | 2023-02-08 | NCT05717764 |